Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor- β signaling in cooperation with active *Kras* expression

Hideaki Ijichi,¹ Anna Chytil,^{1,4} Agnieszka E. Gorska,^{1,4} Mary E. Aakre,^{1,4} Yoshio Fujitani,^{2,3,5} Shuko Fujitani,^{2,3,6} Christopher V.E. Wright,^{2,3} and Harold L. Moses^{1,4,7}

¹Department of Cancer Biology, Vanderbilt University, Nashville, Tennessee 37232, USA; ²Cell and Developmental Biology, Vanderbilt University, Nashville, Tennessee 37232, USA; ³Vanderbilt University Program in Developmental Biology, Vanderbilt University, Nashville, Tennessee 37232, USA; ⁴The Vanderbilt-Ingram Comprehensive Cancer Center, Vanderbilt University, Nashville, Tennessee 37232, USA

Pancreatic ductal adenocarcinoma (PDAC) is an almost uniformly lethal disease in humans. Transforming growth factor- β (TGF- β) signaling plays an important role in PDAC progression, as indicated by the fact that *Smad4*, which encodes a central signal mediator downstream from TGF- β , is deleted or mutated in 55% and the type II TGF- β receptor (*Tgfbr2*) gene is altered in a smaller subset of human PDAC. Pancreas-specific *Tgfbr2* knockout mice have been generated, alone or in the context of active *Kras* (*Kras*^{G12D}) expression, using the Cre-loxP system driven by the endogenous *Ptf1a* (*pancreatic transcription factor-1a*) locus. Pancreas-selective *Tgfbr2* knockout alone gave no discernable phenotype in 1.5 yr. Pancreas-specific *Kras*^{G12D} activation alone essentially generated only intraepithelial neoplasia within 1 yr. In contrast, the *Tgfbr2* knockout combined with *Kras*^{G12D} expression developed well-differentiated PDAC with 100% penetrance and a median survival of 59 d. Heterozygous deletion of *Tgfbr2* with *Kras*^{G12D} expression also developed PDAC, which indicated a haploinsufficiency of TGF- β signaling in this genetic context. The clinical and histopathological manifestations of the combined *Kras*^{G12D} expression and *Tgfbr2* knockout mice recapitulated human PDAC. The data show that blockade of TGF- β signaling and activated Ras signaling cooperate to promote PDAC progression.

[**Keywords:** *Kras*; pancreas-specific knockout; pancreatic ductal adenocarcinoma; *Ptf1a*; TGF- β ; type II TGF- β receptor]

Supplemental material is available at <http://www.genesdev.org>.

Received July 28, 2006; revised version accepted September 27, 2006.

Pancreatic cancer is one of the leading causes of cancer death in many countries, and also is one of the most lethal diseases, with a <5% 5-yr survival rate (Warshaw and Fernandez-del Castillo 1992; Hezel et al. 2006; Jemal et al. 2006). Poor survival is likely because most of the patients are already at an unresectable stage when diagnosed. Moreover, even with a successful resection, most patients have recurrence within a year, and the tumors

are resistant to all forms of conventional therapies. Since the most common form is pancreatic ductal adenocarcinoma (PDAC), to establish a good animal model that recapitulates aggressive full-blown human PDAC is of high importance for a better understanding of this disease, and for development of better means of early detection and treatment.

Previous histological and molecular studies have suggested a model of disease evolution through a preinvasive state, termed pancreatic intraepithelial neoplasia (PanIN), along with accumulating specific genetic alterations (Hruban et al. 2001). An activating point mutation of the *Kras* proto-oncogene is found in PanIN lesions and with increasing frequency at later stages, and in >90% of

Present addresses: ⁵Juntendo University, Tokyo 113-8421, Japan; ⁶Osaka University, Osaka 565-0871, Japan.

⁷Corresponding author.

E-MAIL hal.moses@vanderbilt.edu; FAX (615) 936-1790.

Article is online at <http://www.genesdev.org/cgi/doi/10.1101/gad.1475506>.

invasive PDAC. *Kras* mutation is thought to be a tumor-initiating event (Klimstra and Longnecker 1994; Rozenblum et al. 1997). Genetic and epigenetic inactivations of tumor suppressor genes, including *p16^{INK4a}*, *p53*, and *Smad4* (*DPC4*), increase in frequency in progressively higher PanIN stages, and are found in ~90%, 75%, and 55%, respectively, of invasive PDACs (Rozenblum et al. 1997). Therefore, activation or inactivation of these signaling pathways seems to have a crucial role in PDAC formation.

Recently, genetically engineered mouse PDAC progression models were obtained by pancreas-specific conditional activation or knockout of those clinically relevant PDAC-related genes, using the promoters *Pancreatic and duodenal homeobox gene 1* (*Pdx1*) or *pancreatic transcription factor 1a* (*Ptf1a*, or *p48*). *Pdx1* and *Ptf1a* are both expressed at the pancreas epithelial progenitor stage and are essential for pancreas development and differentiation (Offield et al. 1996; Kawaguchi et al. 2002). The *Pdx1-Cre;LSL-Kras^{G12D/+}* or *Ptf1a^{cre/+};LSL-Kras^{G12D/+}* model (Hingorani et al. 2003), both of which excise the stop codon between *loxP* sites in the *LSL-Kras^{G12D}* allele, generate physiological levels of expression of the constitutively active mutant *Kras* (*Kras^{G12D}*) transcript from the native *Kras* promoter. Although all three epithelial lineages of the pancreas (ductal, acinar, islet) have a genetic modification in these mice, they developed pancreatic ductal neoplasms, which recapitulated human PanIN lesions. The lesions slowly progress further into advanced PDAC with a median survival of 15 mo (Hingorani et al. 2005), suggesting again that the *Kras* activation is a tumor-initiating event and that specific accelerative events are required for human PDAC progression. Based on this *LSL-Kras^{G12D}* model, three representative studies of invasive PDAC models were reported (Aguirre et al. 2003; Hingorani et al. 2005; Bardeesy et al. 2006). In one model—*Kras^{G12D}* expression plus *Ink4a/Arf* allele knockout (*Pdx1-Cre;LSL-Kras^{G12D/+};Ink4a/Arf^{lox/lox}*)—there was highly invasive PDAC with a median survival of 8 wk (Aguirre et al. 2003). There were, however, relatively few macrometastatic lesions. In addition, one-third of the PDAC was accompanied by spindle cell or sarcomatoid histology, which is an infrequent phenotype in human PDAC. *Pdx1-Cre;LSL-Kras^{G12D/+};LSL-Trp53^{R172H/+}*, which had *Kras^{G12D}* expression plus *Trp53* inactivation each driven by their respective native promoters, demonstrated highly metastatic PDAC with a median survival of 5 mo (Hingorani et al. 2005). The histology exhibited differentiated ductal adenocarcinoma, recapitulating human PDAC, but the survival was much longer than *Pdx1-Cre;LSL-Kras^{G12D/+};Ink4a/Arf^{lox/lox}*. The latest study comparing various combinations of *Pdx1-Cre;LSL-Kras^{G12D/+}* with *p16^{-/-}*, *Ink4/Arf^{lox/lox}*, and *p53^{lox/lox}* showed PDACs with various tumor latency and various histological distribution of differentiated adenocarcinoma, anaplastic carcinoma, and sarcomatoid tumor, depending on the type of knockout (Bardeesy et al. 2006). Among them, homozygous mutants of either *p16^{INK4a}* or *p53* showed much shortened tumor latency and a greater frequency of undifferentiated histol-

ogy. Mice with a wild-type *p16^{INK4a}* allele in their genotype showed a tendency to have differentiated PDAC histology. These published models formed extra-pancreatic tumors as well because *Pdx1* is also expressed in extra-pancreas regions (Offield et al. 1996); sometimes those tumors were aggressive, which suggested that a more specific pancreatic mouse model might be preferable.

Among the clinically relevant PDAC-related tumor suppressor pathways described above, the transforming growth factor- β (TGF- β)–Smad signaling pathway still remains to be investigated in the context of active *Kras* expression for modeling human PDAC. TGF- β –Smad signaling is well known to have growth inhibitory effects on epithelial cells, among its multiple physiological functions (Miyazono et al. 2000). Loss of this signaling might cause an escape of cells from appropriate growth regulation, which would result in tumor formation in a variety of organs. *Smad4*, which encodes a central signal mediator downstream from the TGF- β receptors, is frequently inactivated in invasive human PDAC as described above (Hahn et al. 1996), and it is by far the most frequent among human sporadic cancers. The *type II* TGF- β receptor (*Tgfr2*) gene is mutated or deleted in a smaller subset of human PDAC (Goggins et al. 1998). Together, these findings suggested that *Smad4* inactivation or impaired TGF- β signaling might be contributing to the highly invasive and metastatic PDAC cell characteristics.

On the other hand, TGF- β signaling is considered to enhance tumor progression in the later stages (Derynck et al. 2001). With regard to the pancreas, TGF- β isoforms 1, 2, and 3 are highly expressed in human PDAC tissue, a feature that is correlated with poor prognosis (Friess et al. 1993), which suggests the tumor-promoting effect of this cytokine. TGF- β signaling is also important in pancreas development. It is reported that TGF- β 1 promotes development of endocrine cells and disrupts epithelial branching and acinar formation in vitro (Sanvito et al. 1994), while dominant-negative *Tgfr2* transgenic mice showed increased proliferation of acinar cells and severely perturbed acinar differentiation in vivo (Bottinger et al. 1997).

We have conditionally inactivated *Tgfr2* using Cre/*loxP* technology (Chytil et al. 2002) and also reported that *Tgfr2* knockout in the mammary gland epithelia in addition to polyoma virus middle T antigen expression shortened tumor latency and enhanced lung metastasis (Forrester et al. 2005), which indicates a predominant tumor suppressor effect of TGF- β signaling on breast cancer progression. Here, we report the effect of *Tgfr2* knockout on pancreas development, and further on PDAC progression in the context of active *Kras* expression. In contrast to the dominant-negative *Tgfr2* transgenic mice study, pancreas epithelium-specific *Tgfr2* knockout revealed no obvious effect on normal pancreas development. *Tgfr2* knockout with active *Kras* expression dramatically promoted PDAC progression from mouse PanIN (mPanIN) lesions, and the PDAC recapitulated the human disease extremely well. These findings indicate that disrupted TGF- β signaling and activated

Ras signaling might contribute synergistically to PDAC formation and that this model is a most promising avenue for attacking this difficult human disease.

Results

Normal pancreas development in the pancreas epithelium-specific *Tgfr2* knockout mice

To investigate the effect of TGF- β signaling in pancreas development and disease, we first generated pancreas epithelium-specific *Tgfr2* knockout mice by crossing the *Ptf1a*^{cre/+} mice (Kawaguchi et al. 2002) with the *Tgfr2*^{flox/flox} mice (Chytil et al. 2002), resulting in the genotype *Ptf1a*^{cre/+};*Tgfr2*^{flox/flox}. By using the *Ptf1a* promoter, the Cre recombination and consequent *Tgfr2* knockout were expected to take place in all three pancreas epithelia lineages: duct, acinar, and islet cells. While the *Tgfr2*^{-/-} mice were embryonic lethal (Oshima et al. 1996), the *Ptf1a*^{cre/+};*Tgfr2*^{flox/flox} mice were born at the expected frequency. PCR analysis de-

monstrated the recombined allele of the *Tgfr2* gene in the pancreas, and Cre-recombinase expression was uniformly detected in the acinar, ductal, and islet cells by X-gal staining of the mice further crossed with Rosa26 reporter mice (genotype: *Ptf1a*^{cre/+};*Tgfr2*^{flox/flox};*Rosa26r*) (Soriano 1999), which confirmed the expected *Tgfr2* knockout in a pancreas epithelium-specific manner (Fig. 1A–C).

The pancreas of *Ptf1a*^{cre/+};*Tgfr2*^{flox/flox} mice appeared very normal (Fig. 1D). We analyzed the expression of islet cell markers, glucagon, insulin, somatostatin, pancreatic polypeptide, and the acinar cell marker amylase, which revealed that somatostatin-positive cells were more frequently observed in the *Tgfr2* knockout mice at the 1-d and 7-wk stages with statistical significance ($p < 0.01$). However, this difference disappeared by 12 wk of age, and other markers showed no difference between the knockout and control pancreas (Fig. 1E). Glucose tolerance tests and body weight monitoring also showed no significant changes compared with the controls (data not shown).

Figure 1. Normal pancreas development in *Tgfr2* knockout mice. (A) PCR detected *Tgfr2* allele recombination in the pancreas tissues of 1-d to 24-wk-old mice. (Top) PCR to detect *Tgfr2* allele recombination. The recombined allele was detected in the *Ptf1a*^{cre/+};*Tgfr2*^{flox/flox} and *Ptf1a*^{cre/+};*Tgfr2*^{flox/+} mice throughout the ages examined. (Bottom) Genotyping PCR to detect floxed and wild-type *Tgfr2* alleles. Some floxed alleles appeared to be diminished in those mice that showed the allele recombination. (Rec) Recombined allele; (fl) floxed allele; (wt) wild-type allele of *Tgfr2* gene; (fl/fl) *Ptf1a*^{cre/+};*Tgfr2*^{flox/flox} mice; (fl/+) *Ptf1a*^{cre/+};*Tgfr2*^{flox/+} mice; (+/+) *Tgfr2*^{flox/flox} mice. (B,C) β -Galactosidase in situ staining. Cre recombination was homogeneously observed all through the pancreas of *Ptf1a*^{cre/+};*Tgfr2*^{flox/flox};*Rosa26r* mice (B), but not in that of *Tgfr2*^{flox/flox};*Rosa26r* mice (C). (D) H&E staining of 1.5-yr-old pancreas of the *Ptf1a*^{cre/+};*Tgfr2*^{flox/flox} mouse. The pancreas was normally developed and has no abnormal findings in *Tgfr2* knockout mice. (E) Immunohistochemistry of endocrine and exocrine pancreas markers at 7 wk of age. Insulin, glucagon, and amylase staining showed no difference. Somatostatin expression was more prominent in the *Tgfr2* knockout mice at this stage. (Control) *Tgfr2*^{flox/flox} mice; (*Tgfr2* KO) *Ptf1a*^{cre/+};*Tgfr2*^{flox/flox} mice. Bars: B,C,E 250 μ m; D, 500 μ m.

Thus, the knockout of *Tgfb2* had only subtle effects on pancreas development and the mice have shown no phenotype up to 18 mo. The apparently normal pancreas in the *Ptf1a^{cre/+};Tgfb2^{flox/flox}* mice indicated that the blockade of TGF- β signaling in the pancreatic epithelium was insufficient to initiate pancreas tumor formation. Other proto-oncogene activation might be required for spontaneous tumor initiation.

Knockout of Tgfb2 rapidly promotes mutant Kras-induced PanIN progression to ductal adenocarcinoma

The *Pdx1-Cre;LSL-Kras^{G12D/+}* or *Ptf1a^{cre/+};LSL-Kras^{G12D/+}* mice have been reported to have mPanIN lesions as early as at 2 wk of age, but most of the lesions did not progress into advanced cancer within 1 yr (Hingorani et al. 2003). We crossed the *LSL-Kras^{G12D/+}* mice with our *Tgfb2* knockout mice and generated mice of the genotype *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfb2^{flox/flox}*. These mice had active Kras expression plus *Tgfb2* knockout both in a pancreas epithelium-specific manner.

These mice, which were obtained at the expected Mendelian frequency at birth, began to demonstrate abdominal distension at ~6–7 wk of age, which allowed us to “diagnose” their pancreatic tumor. The distension was due to ascites and the tumor itself, which was firm and palpable through the skin. The mice frequently demonstrated weight loss, bloody ascites, and sometimes jaundice, and were sacrificed when they appeared to be in distress; some died suddenly. The median survival was 59 d (8.4 wk) (Fig. 2A–C; Supplementary Table 1). These symptoms recapitulate well those frequently found in human PDAC. No animals with other genotypes showed any symptoms at this stage, except for one case (*Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfb2^{flox/+}*) that had a cystic dilatation of the obstructed main pancreatic duct. A Kaplan-Meier curve showed a dramatically shortened survival of the *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfb2^{flox/flox}* with statistical significance ($p < 0.001$) (Fig. 2A).

The mice were dissected when they became distressed, mostly at 7–10 wk of age. The *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfb2^{flox/flox}* tumor uniformly occupied the whole pancreas and was irregularly shaped with a homo-

Figure 2. *Kras^{G12D}* expression plus *Tgfb2* knockout developed aggressive pancreatic tumors. (A) Kaplan-Meier curve. *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfb2^{flox/flox}* mice (*Kras + Tgfb2^{KO}*) showed a dramatically shortened survival (median survival: 59 d). *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfb2^{flox/+}* mice (*Kras + Tgfb2^{L/+}*) also showed a shortened survival compared with the controls after 200 d. The control group includes the genotypes of *LSL-Kras^{G12D/+};Tgfb2^{flox/flox}*, *Ptf1a^{cre/+};Tgfb2^{flox/flox}*, *Ptf1a^{cre/+}*, and *Ptf1a^{cre/+};LSL-Kras^{G12D/+}*. (B,C) Gross images of the pancreatic tumor from *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfb2^{flox/flox}* mice. The abdomen was distended due to the tumor (arrowhead) and ascites. (B) Note the bloody ascites in this mouse. The tumor (arrowhead) occupied the entire pancreas and compressed adjacent organs. (C) Note the apparent jaundice in this mouse. (D) PCR detected recombination of the *LSL-Kras^{G12D}* and floxed *Tgfb2* alleles in a pancreas-specific manner. (Rec) Recombined allele; (wt) wild-type allele. The genotypes of mice are K133, K59, K131, K143: *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfb2^{flox/flox}*; K127: *Ptf1a^{cre/+};LSL-Kras^{G12D/+}*; K130: *Ptf1a^{cre/+};Tgfb2^{flox/flox}*; K129: *LSL-Kras^{G12D/+};Tgfb2^{flox/flox}*; K125: wild-type. (P) Pancreas; (L) liver.

geneous white and firm appearance (Fig. 2B,C). No normal pancreas tissue was seen macroscopically. The duodenum loop was compressed by the tumor, resulting in obvious duodenal and gallbladder dilatation. Splenomegaly was also frequently observed. At this stage, the *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{flox/+}* and *Ptf1a^{cre/+};LSL-Kras^{G12D/+}* mice showed only single or a couple of 1-mm-sized nodules, if any, which were also white and firm, while the vast majority of the pancreas still appeared normal. The other genotype pancreases (*LSL-Kras^{G12D/+};Tgfr2^{flox/flox}*, *Ptf1a^{cre/+};Tgfr2^{flox/flox}*, and *Ptf1a^{cre/+}*) showed no abnormal appearance. In those pancreatic tissues, the recombined alleles of *Kras* and *Tgfr2* genes were detected as expected according to the genotype, while the nonpancreas tissue (liver), a negative control, showed no recombination (Fig. 2D).

Upon microscopic examination, the *Ptf1a^{cre/+};LSL-Kras^{G12D/+}* mice demonstrated mPanIN lesions as reported previously (Hingorani et al. 2003) within a large

amount of normal pancreas that contained well-organized acinar, ductal, and islet tissue (Fig. 3A). The *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{flox/+}* mice showed similar histology. However, both genotypes showed no PDAC lesions that had grown beyond the basement membrane at the 7–10-wk stage. The *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{flox/flox}* tumors exhibited uniformly well-differentiated glandular architecture ($n = 25$), which occupied the entire pancreas, resulting in almost complete loss of normal pancreatic tissue. The carcinoma cells frequently showed nuclear atypia and invasion beyond the basement membrane (Fig. 3B–D). The nascent invasion of tumor cells into the stroma was also revealed by pan-cytokeratin immunostaining (Fig. 3E). Carcinoma cells showed positive ductal markers, CK19 and mucin (Fig. 3F,G), and were negative for the acinar and islet marker, amylase, and insulin (data not shown), indicating ductal adenocarcinoma. Notably, the tumors were also richly distributed with a stromal component,

Figure 3. Histology of the *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{flox/flox}* pancreatic tumors. *Ptf1a^{cre/+};LSL-Kras^{G12D/+}* (A,H,I) and *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{flox/flox}* (B–G,I,K,L) pancreas (7–9 wk of age). (A–D) H&E staining. (A) The *Ptf1a^{cre/+};LSL-Kras^{G12D/+}* mice showed mPanIN lesions surrounded by stromal capsule and still abundant normal pancreas areas. (B) The *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{flox/flox}* pancreas showed well-differentiated ductal adenocarcinoma, with a rich stromal component. Some areas still retained nuclear polarity and abundant cytoplasm (C); however, others showed nuclear atypia and a high nuclear–cytoplasmic ratio (D). (E) Pan-cytokeratin staining revealed tumor epithelial cells invading into the stromal regions. Positive alcian blue (F) and CK-19 staining (G) confirmed the mucin-producing (blue), ductal phenotype of the tumor. Vimentin (H,I) and smooth muscle actin (J,K) staining was negative in the tumor epithelia, whereas prominent stromal infiltration (strong positive) was observed. (L) H&E staining of the *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{flox/flox}* tumor also showed acinar–ductal metaplasia lesions. The arrows indicate acinar–ductal metaplasia (ductal lesions containing acinar granules). The arrowheads indicate an mPanIN-1B lesion. Bars: B,E, 250 μ m; A, C,D,F–L, 125 μ m.

showing positive for vimentin and smooth muscle actin staining (Fig. 3B,I,K), which was also found in the area surrounding mPanIN lesions in the *Ptf1a^{cre/+};LSL-Kras^{G12D/+}* pancreas (Fig. 3H,J). This indicated that stromal expansion had started in the early tumorigenesis stages. Moreover, a distinct and important feature of this mouse model is that the *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfb2^{lox/lox}* tumors did not show sarcomatoid architecture, which was seen in one-third of the *Kras^{G12D}* activation plus *Ink4a/Arf* knockout model (Aguirre et al. 2003). This feature is seen infrequently in human PDAC, providing another line of evidence that our mouse model is a close approximation of aggressive human PDAC. The penetrance of tumor appearance across all mice of the *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfb2^{lox/lox}* genotype examined was 100%, and tumors were always accompanied by a whole panel of mPanINs and acinar–ductal metaplasia lesions (Fig. 3L).

The *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfb2^{lox/lox}* PDACs and *Ptf1a^{cre/+};LSL-Kras^{G12D/+}* mPanINs were strongly positive for EGFR, erbB2/Her2, and phospho-ERK (Fig. 4), while normal pancreatic ducts showed faint or negative staining (data not shown). This indicates that these signals were activated from the early stage of tumors, another feature closely paralleling the human disease (Hezel et al. 2006). E-cadherin was well maintained in the mPanIN lesions of *Ptf1a^{cre/+};LSL-Kras^{G12D/+}* mice, demonstrating typical cell–cell junctional staining, whereas the PDAC lesions of *Ptf1a^{cre/+};LSL-Kras^{G12D/+}*;

Tgfb2^{lox/lox} mice revealed heterogeneity, with some areas completely lacking the junctional staining, while in many other areas it was still retained (Fig. 4). These results were consistent with another PDAC model (Hingorani et al. 2005) and suggested that the tumor was developing epithelial discontinuity and more invasive characteristics.

The pancreas epithelium-specific knockout of *Tgfb2* in the context of *Kras^{G12D}* expression revealed a dramatic enhancement of pancreatic tumor progression, and the tumor recapitulated human PDAC very closely.

Age progression of lesions in *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfb2^{lox/lox}* model

We next examined mice at earlier ages to assess the severity of development of these lesions over the postnatal period. At 3.5 wk of age, the *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfb2^{lox/lox}* pancreas showed less frequent, but multifocal, isolated mPanINs and acinar–ductal metaplasia lesions surrounded by abundant normal pancreas area (Supplementary Fig. 1A–C), as was also observed in similar-age *Ptf1a^{cre/+};LSL-Kras^{G12D/+}* mice. At this stage, mPanIN-type lesions could be clearly distinguished from those representing acinar–ductal metaplasia; the distribution of mPanIN-1A, mPanIN-1B, mPanIN-2, and mPanIN-3 was 22%, 39%, 28%, and 11%, respectively. No invasive cancer lesion was found at this stage. At 5 wk of age, the distribution had shifted toward 8.3%,

Figure 4. Immunostaining of the *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfb2^{lox/lox}* and *Ptf1a^{cre/+};LSL-Kras^{G12D/+}* pancreatic tumors. EGFR and phospho-ERK were highly expressed both in the *Ptf1a^{cre/+};LSL-Kras^{G12D/+}* mPanIN lesions (top panels) and *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfb2^{lox/lox}* PDAC lesions (bottom panels). erbB2/Her2 was also expressed in both lesions; however, more advanced stage lesions of the latter showed weaker or negative staining. E-cadherin immunofluorescence revealed a regular cell-junctional staining in the mPanIN lesions, whereas the PDAC lesions frequently showed nonjunctional, disorganized E-cadherin expression. (Green) E-Cadherin; (blue) DAPI. (Kras PanIN) mPanIN in the *Ptf1a^{cre/+};LSL-Kras^{G12D/+}* mice; (Kras + RIIKO PDAC) PDAC in the *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfb2^{lox/lox}* mice. Bars, 125 μ m.

20%, 17%, and 29%, respectively, in the same order, and invasive cancer lesions, which had invaded beyond the basement membrane, already accounted for 26% in the *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{flox/flox}* mice (Supplementary Fig. 1D,E). Mice with other genotypes had no PDAC lesions even at 7–10 wk of age, when the whole pancreas in *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{flox/flox}* mice had already become substituted by the tumor, resulting in loss of almost all normal acinar and islet tissue (Fig. 3B–D). We suggest that the order of appearance of the progressively more severe lesions is consistent with the hypothesis that there is a progression through a preceding stage of mPanIN lesion.

Invasive potential of the Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{flox/flox} PDAC

Lungs and livers of the tumor-bearing mice were subjected to histological analysis for metastasis (procedure in Supplemental Material). Although the tumors were very large, no distant metastasis was observed at 7–10 wk. The tumors showed minimal invasion into the duodenum, intrapancreatic lymph nodes, lymphatic channels, and/or nerve of peripheral pancreas, all of which are commonly found in human PDAC. Under this late-stage tumor burden, portal vein thrombosis was frequently detected (8/25 = 32%). The main trunk of the portal vein was completely obstructed with thrombus frequently accompanied by fibroblast involvement, which resulted in multiple necrotic areas in the distal liver parenchyma (Supplementary Fig. 2). The mice also demonstrated paraplegia in three cases. This was likely because of circulation failure due to direct oppression of large vessels by the rapidly growing tumor.

Although most *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{flox/flox}* mice had to be sacrificed at 7–10 wk of age, three of this genotype survived up to 24–27 wk. All of them demonstrated PDAC with prominent desmoplasia and liver metastasis, and two showed lung metastasis, diaphragmatic and duodenal invasion, and peritoneal dissemination (Supplementary Fig. 2). These findings revealed that the *Kras^{G12D}* expression plus *Tgfr2* knockout tumor had substantial invasive and metastatic potential, again recapitulating aggressive human PDAC. The age of ~25 wk was similar to the median survival of the *Kras^{G12D}* expression plus *p53* inactivation model described previously (Hingorani et al. 2005). It is possible that the development of invasion and metastasis in all of the *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{flox/flox}* mice might require a period longer than most of them in this study could survive.

Molecular analysis of the Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{flox/flox} tumor cells

Next, we established pancreatic cell lines from the *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{flox/flox}* PDAC, as well as from the mPanIN-type lesions in the *Ptf1a^{cre/+};LSL-Kras^{G12D/+}* pancreas. To address whether the mutant

Kras expression plus *Tgfr2* knockout is an independent tumorigenesis pathway from those of previous mouse models, the status of other tumor suppressor genes highly related to human PDAC, *p16^{INK4a}*, *p53*, and *Smad4* was examined using these cell lines. The coding sequences of those genes in several primary PDAC cell lines revealed no significant mutations, although one silent point mutation in *Smad4* in one cell line was found (data not shown).

In Western blotting, *Smad4* protein expression was detected in all cell lines examined (Fig. 5A). *p53* was also expressed in most cell lines, and γ -irradiation induced *p53* protein expression in most of the cell lines examined, which indicated normal *p53* function in these cells (Fig. 5A,B). In contrast, the *p16^{INK4a}* protein level varied among the cell lines, and *p19^{ARF}* protein, which is derived from the alternative reading frame of the DNA locus shared with *p16^{INK4a}*, was not detected in any cell lines including the *Ptf1a^{cre/+};LSL-Kras^{G12D/+}* cells (Fig. 5A; data not shown). In RT-PCR analysis, *p16^{INK4a}* mRNA expression correlated well with that of protein, while *p19^{ARF}* mRNA expression was detected in most of the cell lines (Fig. 5C). The discrepancy of *p19^{ARF}* mRNA and protein expression remains to be elucidated.

The type II TGF- β receptor protein (T β RII) expression

Figure 5. Molecular analysis of the *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{flox/flox}* PDAC cell lines. (A) Western blot analysis using total cell lysates of the established pancreatic cell lines from the *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{flox/flox}* PDAC (*Kras* + *Tgfr2*KO cells) and *Ptf1a^{cre/+};LSL-Kras^{G12D/+}* pancreas (*Kras* cells) revealed intact *Smad4*, *p53* protein expression in most of the cell lines and loss of T β RII only in the *Kras* + *Tgfr2*KO cell lines. *p16^{INK4a}* protein was variably expressed even in the *Kras* cell lines. (Actin) Loading control. (B) Analysis of *p53* function by γ -irradiation. *p53* protein was induced by γ -irradiation in all cell lines examined. (Tubulin) Loading control. (C) RT-PCR for *p16^{INK4a}* and *p19^{ARF}* mRNA expression. *p16^{INK4a}* mRNA level was variable in the cell lines, which was well correlated with the protein level. The *p19^{ARF}* mRNA level was relatively consistent with that of *p16^{INK4a}*. (GAPDH) Loading control. (D) TGF- β -Smad signaling analysis. TGF- β -induced *Smad3* phosphorylation was found only in the *Kras* cells (T β RII-intact), but was completely lost in all the *Kras* + *Tgfr2*KO cells. (Actin) Loading control.

and TGF- β -Smad signaling were also analyzed. As expected by the Cre-mediated deletion, T β RII expression was lost in all PDAC cell lines examined, and upon TGF- β 1 stimulation, downstream Smad3 phosphorylation was abrogated in those PDAC cell lines, while it was clearly observed in the *Tgfr2*-intact cells (Fig. 5A,D).

PI3K-Akt signaling was also examined in those cell lines. It was expected that both mPanIN and PDAC cells have Akt activation, since the PI3K-Akt pathway is one of those downstream from the active Kras signals. On the other hand, the TGF- β signal activates the PI3K-Akt pathway, sometimes synergistically with the Kras signal (Janda et al. 2002). Our results showed Akt phosphorylation in both PDAC and mPanIN cells (Supplementary Fig. 3), which indicated that blockade of the TGF- β signal does not inhibit PI3K-Akt signaling in the *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{flox/flox}* PDAC cells, and it is consistent with the cumulative data suggesting activation of this signal in human PDAC (for review, see Hezel et al. 2006). Cyclin D1, cyclin-dependent kinase 2 (CDK2), and CDK4 protein expression was also examined. Both the mPanIN and PDAC cell lines examined expressed abundant amounts of these proteins (Supplementary Fig. 3).

Taken together, the mutant *Kras* expression plus *Tgfr2* knockout was a sufficient combination for aggressive PDAC formation and progression through to large tumors with metastatic potential. Although some PDAC cells showed loss of both p16^{INK4a} and T β RII proteins, others retained intact p16^{INK4a} protein expression. The precise relation of the status of *Tgfr2* and p16^{INK4a}, as well as p19^{ARF}, remains to be investigated.

Heterozygous loss of Tgfr2 promotes PDAC progression along with mutant Kras expression

Reduced TGF- β signaling (haploinsufficiency at the *Tgfr2* locus) also seems to interact synergistically with expression of the activated Kras protein in terms of inducing tumors. *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{flox/+}* mice also have a reduced survival compared with control animals and a much longer latency than the *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{flox/flox}* (Fig. 2A). Different from the *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{flox/flox}* mice, most of the *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{flox/+}* mice did not show obvious symptoms (abdominal distension, weight loss, palpable hard tumor, ascites, or jaundice). When dissected at ~200 d or later stage, firm, white-colored nodule(s) were frequently palpable in the pancreas head and/or body area; however, the tail area appeared normal.

The tumors in *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{flox/+}* mice had a similar histology of well-differentiated ductal adenocarcinoma to that of the *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{flox/flox}* tumors (Fig. 6A). Notably, the area of hard, white-colored mass in the pancreas head dominantly showed ductal adenocarcinoma histology, while the area of normally appearing pancreas tail dominantly showed mucin-rich glandular architecture corresponding to mPanIN-1B or mPanIN-2 (Fig. 6B). Normal pancreas structure had almost disappeared already.

These tumors frequently demonstrated gross metasta-

sis to the liver and lung, direct invasion to the duodenum, and also peritoneal dissemination (Supplementary Table 2). The frequency of metastasis or invasion was much higher in the *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{flox/+}* tumors dissected (6/12 = 50%) than in the *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{flox/flox}* tumors, although a certain number of the former cohort are still alive and must be examined later. It is suggested again that the latter cases could not survive long enough for metastasis or invasion due to the enormous tumor burden.

To determine whether the tumor had lost the wild-type allele of the *Tgfr2* gene through loss of heterozygosity (LOH), we performed laser-capture microdissection to obtain tumor epithelial DNA for subsequent PCR analysis. Both the primary and metastatic tumors still retained the wild-type allele of the *Tgfr2* gene (Fig. 6C). The *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{flox/+}* PDAC cell lines retained the wild-type *Tgfr2* allele and showed T β RII protein expression and Smad3 phosphorylation upon TGF- β stimulation, indicating that T β RII protein function was also retained in those tumor cells (Supplementary Fig. 4), although some cells showed LOH and lost T β RII expression, which might be secondary changes arising during cell culture. Smad4 protein was also expressed in all the cells examined (Supplementary Fig. 4). Taken together, it is still possible that point mutation of the *Smad3* or *4* gene caused biallelic inactivation of the TGF- β -Smad pathway; the data indicate that complete disruption of T β RII signaling is not necessarily required for PDAC formation, and haploinsufficiency of TGF- β signaling might be associated with PDAC progression, in the context of the mutant *Kras* expression.

Survival observation of *Ptf1a^{cre/+};LSL-Kras^{G12D/+}* mice has still been ongoing. Among eight mice observed for >200 d, one mouse developed metastatic pancreatic tumor at 249 d of age. For precise statistical analysis between the *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{flox/+}* and *Ptf1a^{cre/+};LSL-Kras^{G12D/+}* mice, longer observation of the *Ptf1a^{cre/+};LSL-Kras^{G12D/+}* group is required. However, there appears to be a clear difference in terms of tumor frequency, latency, and histology between these two lines. By the time the first invasive tumor developed in the *Ptf1a^{cre/+};LSL-Kras^{G12D/+}* line, seven invasive tumors had occurred out of 25 *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{flox/+}* mice (7/25 = 28%). Thereafter, 18 of 25 mice developed invasive pancreatic tumor (18/25 = 72%) with median survival 347 d. According to the longer observations in the published studies, the median survival of the *Kras*-activated mice was described as ~15 mo (Hingorani et al. 2005) or 57 wk (Bardeesy et al. 2006), which are longer than that of the *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{flox/+}* group in our study, although the latency might be affected by the difference of background strains.

Notably, three of eight *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{flox/+}* tumors examined demonstrated a dominant sarcomatoid histology (50% or more) as well as the ductal adenocarcinoma (Fig. 6D-F; Supplementary Table 2). The sarcomatoid feature appeared similar to those in the previously described models (Aguirre et al. 2003; Bar-

Figure 6. Haploinsufficiency of *Tgfr2* in the context of *Kras*^{G12D} expression promoted PDAC progression. (A,B) H&E staining of 32-wk-old *Ptf1a*^{cre/+}; *LSL-Kras*^{G12D/+}; *Tgfr2*^{fl/+} mouse pancreas. (A) Well-differentiated ductal adenocarcinoma in the pancreas head region. (B) mPanIN lesions were dominant in the pancreas tail region. (C) LOH analysis by PCR after laser-capture microdissection. DNA was extracted from the primary pancreas tumor epithelia, metastatic liver tumor epithelia, normal liver, or normal duodenum of the *Ptf1a*^{cre/+}; *LSL-Kras*^{G12D/+}; *Tgfr2*^{fl/+} mice, using laser-capture microdissection. Subsequent PCR showed that all primary pancreas tumor and one metastatic liver tumor epithelia clearly retained the wild-type *Tgfr2* allele (K372 P, K374 P and M, K388 P1 and P2), indicating a lack of LOH. (K372, K374, K388) *Ptf1a*^{cre/+}; *LSL-Kras*^{G12D/+}; *Tgfr2*^{fl/+} mice; (K375 cells) a cell line of *Ptf1a*^{cre/+}; *LSL-Kras*^{G12D/+}; *Tgfr2*^{fl/fl} mouse PDAC. (L) Normal liver; (D) normal duodenum; (P) primary pancreas tumor epithelia; (M) metastatic liver tumor epithelia; (P1) well-differentiated PDAC epithelia; (P2) poorly differentiated PDAC epithelia; (Rec) recombined; (fl) floxed; (wt) wild-type *Tgfr2* allele. (D–F) H&E staining of 50-wk-old *Ptf1a*^{cre/+}; *LSL-Kras*^{G12D/+}; *Tgfr2*^{fl/fl} mouse pancreas and liver. The tumor showed sarcomatoid histology (s) along with ductal adenocarcinoma lesions (arrow) (D), and both sarcomatoid (s) and ductal tumor (arrow) directly invaded into the liver parenchyma (L) (E,F). Bars: E, 250 μm; A–D,F, 125 μm.

deesy et al. 2006). All the three tumors demonstrated aggressive metastasis and/or direct invasion, in which the spindle-shaped cells were spreading along with the ductal tumor cells (Fig. 6E,F). Again, these sarcomatoid tumors were not observed in the *Ptf1a*^{cre/+}; *LSL-Kras*^{G12D/+}; *Tgfr2*^{fl/fl} mice, indicating a distinct aspect of homozygous and heterozygous knockout of the *Tgfr2* gene. Moreover, the *Pdx1-Cre*; *LSL-Kras*^{G12D/+} and *Ptf1a*^{cre/+}; *LSL-Kras*^{G12D/+} pancreatic tumors, in all the cases published or that we observed, showed a dominant sarcomatoid or a significant poorly differentiated histology, specifically, 100% sarcomatoid in one recent study (Hingorani et al. 2003; Bardeesy et al. 2006). Taken together, heterozygous loss of *Tgfr2*, shown in the *Ptf1a*^{cre/+}; *LSL-Kras*^{G12D/+}; *Tgfr2*^{fl/+} mice, might promote PDAC progression differently from both, the homozygous knockout in the *Ptf1a*^{cre/+}; *LSL-Kras*^{G12D/+}; *Tgfr2*^{fl/fl} mice and intact *Tgfr2* in the *Ptf1a*^{cre/+}; *LSL-Kras*^{G12D/+} mice.

Connective tissue growth factor is strongly expressed in *Ptf1a*^{cre/+}; *LSL-Kras*^{G12D/+}; *Tgfr2*^{fl/fl} PDAC stroma

What is the underlying mechanism in the rapid tumor progression in the *Tgfr2* knockout in the context of the mutant *Kras* expression? Strongly up- or down-regulated

genes in the *Ptf1a*^{cre/+}; *LSL-Kras*^{G12D/+}; *Tgfr2*^{fl/fl} PDAC compared with the *Ptf1a*^{cre/+}; *LSL-Kras*^{G12D/+} mPanIN might provide important clues to understand the mechanism, and lead to the further identification of novel therapeutic targets for human PDAC. In this study we found that connective tissue growth factor (CTGF) was much more strongly expressed in the *Ptf1a*^{cre/+}; *LSL-Kras*^{G12D/+}; *Tgfr2*^{fl/fl} PDAC tissues than in the *Ptf1a*^{cre/+}; *LSL-Kras*^{G12D/+} mPanIN lesions (Fig. 7A–D). Immunohistochemistry revealed that the mPanIN stroma showed negative staining in contrast to the mPanIN epithelia (Fig. 7A,B). In clear contrast to this, the PDAC demonstrated a strong CTGF staining mainly in the stromal area (Fig. 7C,D), which is consistent with the previous report that the main source of CTGF in normal tissue is the stroma (Grotendorst 1997). The expression was especially strong in the stroma adjacent to the tumor epithelia (Fig. 7C,D), which suggested an active non-autonomous tumor–stromal inductive interaction. Since CTGF is known as a downstream target of TGF-β signaling (Grotendorst 1997) and PDAC tissue is also reported to express high levels of TGF-β (Friess et al. 1993), we next examined active TGF-β1 expression in the pancreas tissues by ELISA. It revealed higher TGF-β1 expression in both the *Ptf1a*^{cre/+}; *LSL-Kras*^{G12D/+} mPanIN and the *Ptf1a*^{cre/+}; *LSL-Kras*^{G12D/+}; *Tgfr2*^{fl/fl} PDAC tissues,

Figure 7. CTGF overexpression in the stroma of *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfb2^{lox/lox}* PDAC. CTGF immunohistochemistry of 7-wk-old *Ptf1a^{cre/+};LSL-Kras^{G12D/+}* (A,B) and *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfb2^{lox/lox}* (C,D) mouse pancreas. (A) The *Ptf1a^{cre/+};LSL-Kras^{G12D/+}* pancreas stroma shows negative staining of CTGF. (C,D) The *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfb2^{lox/lox}* PDAC stroma demonstrated strong expression of CTGF. Note that the stroma adjacent to the tumor epithelia especially exhibits high CTGF expression. Bars: C, 500 μ m; A, 250 μ m; B,D, 125 μ m.

in a clear contrast to the control *LSL-Kras^{G12D/+};Tgfb2^{lox/lox}* and the *Ptf1a^{cre/+};Tgfb2^{lox/lox}* pancreas (Supplementary Fig. 5). This suggested that high TGF- β 1 expression might have begun at the mPanIN stage and be sustained through PDAC progression.

Discussion

*Pancreatic tumors arising in the *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfb2^{lox/lox}* recapitulate human PDAC*

The *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfb2^{lox/lox}* mice rapidly developed PDAC, which resembled human disease closely in both symptoms and histopathology. Recently, the consensus regarding the criteria for determining mouse PanIN and PDAC was published, which documented that mouse PDAC, which developed through mPanIN lesions originally from the duct cells, should be considered as a close parallel of human PDAC, with clear distinctions between mPanIN and acinar–ductal metaplasia (Hruban et al. 2006). The tumors in this study exhibited this tumorigenesis pathway as with the previous *LSL-Kras^{G12D}*-based models (Aguirre et al. 2003; Hingorani et al. 2003, 2005). According to molecular analyses of the *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfb2^{lox/lox}* PDAC cell lines, the PDAC could develop without any alteration of other human PDAC-related tumor suppressor genes, *p53*, *Smad4*, and *p16^{INK4a}*, which indicated that the combination of *Tgfb2* knockout and active *Kras*

expression was an independent tumorigenesis pathway of mouse PDAC from those of the previous mouse models. On the other hand, some of the PDAC cell lines showed both *p16^{INK4a}* and *Tgfb2* inactivation. It also suggested that there might be a certain underlying association in the *p16^{INK4a}* and TGF- β signaling pathways, which is similarly found as *p16^{INK4a}* and *Smad4* inactivation in human PDAC (Rozenblum et al. 1997). Taken together, the *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfb2^{lox/lox}* mouse represents a novel mouse model of human PDAC.

The *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfb2^{lox/lox}* tumors uniformly demonstrated well-differentiated ductal adenocarcinoma, but not sarcomatoid tumor, in contrast to the *Pdx1-Cre;LSL-Kras^{G12D/+};Ink4a/Arf^{lox/lox}* model (Aguirre et al. 2003), one-third of which showed sarcomatoid tumor, an infrequent type in human PDAC. Both models similarly showed a very short survival, which was much shorter than that of the *Pdx1-Cre;LSL-Kras^{G12D/+};LSL-Trp53^{R172H/+}* model (median survival: 8.4 wk vs. 5 mo) (Hingorani et al. 2005). The *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfb2^{lox/lox}* tumors also showed distant metastasis, direct invasion, and peritoneal dissemination, only when the mice survived until a similar age to those of the *Pdx1-Cre;LSL-Kras^{G12D/+};LSL-Trp53^{R172H/+}* model, which showed highly metastatic tumors. In the recent study (Bardeesy et al. 2006), *Pdx1-Cre;LSL-Kras^{G12D/+};p53^{lox/lox}*, *Pdx1-Cre;LSL-Kras^{G12D/+};p53^{lox/+}*, and *Pdx1-Cre;LSL-Kras^{G12D/+};p53^{lox/+};p16^{+/-}* show a similar phenotype to human PDAC. Although occasional undifferentiated carcinoma was seen, these three show basically differentiated PDAC with distant metastasis, unless they die early due to the enormous tumor burden. This relationship of metastasis frequency and survival period was also seen in our model. Thus, in terms of short survival and differentiated histology, the *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfb2^{lox/lox}* tumors might be one of the closest mouse models of human PDAC, suggesting the impact of blockade of TGF- β signaling.

These previously described *LSL-Kras^{G12D}*-based models used the *Pdx1* promoter to drive Cre recombinase. In this study, the *Ptf1a^{cre/+}* system showed pancreas-specific, homogeneous Cre recombination, not only in acinar cells but also ductal cells (Fig. 1B,C). In contrast, the *Pdx1-Cre* system shows more heterogeneity in Cre expression (Hingorani et al. 2003). Moreover, the *Ptf1a^{cre/+}* system was more specific to pancreas than the *Pdx1-Cre* model. The *Pdx1-Cre* system developed extra-pancreas tumors (Aguirre et al. 2003; Hingorani et al. 2005), which might affect several aspects of the disease conditions. In contrast, the *Ptf1a^{cre/+}* system did not show any extra-pancreatic phenotype in this study, even in the cerebellum (data not shown), where *Ptf1a* is also highly expressed and important for normal organ development (Hoshino et al. 2005). This suggests that there might be a certain advantageous circumstance in the pancreas, and not in the cerebellum, for tissue-specific context-dependent response of cells in the *Ptf1a^{cre/+}* system; that is, the impact of *Kras^{G12D}* activation and blockade of TGF- β signaling becomes prominent only in the pancreas, not in the cerebellum. This may be because of a

different proliferative mechanism, or prolonged plasticity and proliferative potential in the pancreas compared with the cerebellum, or stromal interaction that is deeper in pancreas than in the brain region. Accordingly, the *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{flox/flox}* mice may have several advantages compared with other existing mouse models.

Underlying mechanism of PDAC progression induced by Tgfr2 knockout in the context of active Kras expression

As described above, the blockade of TGF- β signaling has a great impact on Kras-induced PDAC progression. What is the mechanism underlying the dramatic tumor progression in the *Tgfr2* knockout in the context of active *Kras* expression? Since TGF- β is a growth inhibitor of epithelial cells, it is possible that deprivation of this signal by knockout of *Tgfr2* might confer privileges to those cells for autonomous proliferation, resulting in rapid tumor formation. However, *Tgfr2* knockout alone did not cause any abnormalities up to 1.5 yr of age. It was suggested that *Kras* activation might be required first as a tumor-initiating event, and then the inactivation of either tumor suppressor gene *p16^{INK4a}*, *p53*, *Tgfr2*, or *Smad4* should occur for promoting tumor progression, which seems similar to the clinical findings for human PDAC. It seems also the same in other organs, that *Tgfr2* knockout alone does not initiate tumor formation, unless certain oncogene activation or chemical initiation exists (Forrester et al. 2005; Lu et al. 2006). To clarify the direct effect of TGF- β signal blockade on the mutant Kras-initiated PDAC progression, *Tgfr2* knockdown in the *Ptf1a^{cre/+};LSL-Kras^{G12D/+}* cells using siRNA might provide a better understanding of this tumorigenic process.

TGF- β signaling appears to be important especially in epithelial–stromal interaction (Bierie and Moses 2006). The vast stroma uniformly found in the *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{flox/flox}* tumors also suggested there might be active interaction between the tumor and stroma. In this study, we showed strong CTGF expression in the PDAC stroma, especially the area adjacent to the tumor epithelium, which might reflect an active tumor–stromal interaction. Although CTGF is known as one of the target genes downstream from the TGF- β signal, high levels of TGF- β 1 found in both the PDAC and mPanIN might not be able to explain the clear contrast of CTGF expression between the two, high in PDAC and low in mPanIN stroma. There might be another mechanism in the strong CTGF expression in the PDAC stroma. It was recently reported that CTGF promoted growth and invasion of pancreatic cancer cell lines in vitro, and its specific antibody attenuated orthotopic pancreatic tumor progression in vivo (Aikawa et al. 2006). Therefore, testing the activity of CTGF-blocking antibodies in this new mouse PDAC model might be effective. A positive result in this respect would lend strong support for developing a novel approach for target therapy of PDAC; that is, to target molecules expressed

not just in the tumor epithelium itself but in the stromal cells that provide nonautonomous maintenance and progression signals, as was proposed in a recent study (Lu et al. 2006). In this regard, other stromal components (matrix metalloproteinases, tissue inhibitors of metalloproteinases, etc.) might be further investigated.

The level of TGF- β signal might be a significant determinant of pancreatic tumor formation and histology

The *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{flox/+}* mice also developed PDAC while retaining one wild-type *Tgfr2* allele, which indicated that complete knockout of *Tgfr2* is not always required, but that decreased TGF- β signaling can promote quite severe PDAC progression. The tumors progressed much more slowly than the complete *Tgfr2* knockout, presenting with less symptoms, although resulting in a similar final histology and a more frequent metastatic spread. In terms of decreased level of signaling, reduced *Tgfr2* expression by epigenetic silencing is already reported in human lung and prostate cancer (Zhang et al. 2004; Zhao et al. 2005), although there are controversial studies in pancreatic cancer that showed decreased or increased *Tgfr2* mRNA expression in the tumor tissues (Wagner et al. 1999; Venkatasubbarao et al. 2000). We found a gradation of tumors in the *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{flox/+}* mice, in which the PDAC lesions were frequently located in the pancreas head and body with low-grade mPanIN lesions in the tail area. The same pattern likely exists in earlier-age *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{flox/flox}* mice, according to the 5-wk-old mice study, in which there was a minor invading tumor area in the pancreas head, contained within an abundant normal pancreatic tissue. What determines the difference in propensity to PDAC progression between the pancreas head and tail, which is also seen in human PDAC, remains to be investigated. It is known that the body and tail of the pancreas are derived from the dorsal pancreatic bud, while the head of the pancreas is mostly derived from the ventral pancreatic bud (Werlin 2004). This suggests that the difference of phenotypic response to carcinogenic genetic changes between the pancreas head and tail might be connected to genetic difference of their initial developmental anlagen, the ventral and dorsal buds.

In this study, three among eight *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{flox/+}* mice examined demonstrated sarcomatoid tumor along with well-differentiated PDAC. In contrast, all 25 *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{flox/flox}* mice developed well-differentiated PDAC, and none of them showed sarcomatoid histology. Since the sarcomatoid tumors always accompanied differentiated PDAC, it was likely derived through the mechanism of epithelial–mesenchymal transdifferentiation (EMT). Because the TGF- β signal is known to induce EMT as one of its major functions (Zavadil and Bottinger 2005), the amount of intact TGF- β signaling might be one of the important determinants of pancreatic tumor histology; that is, the more the TGF- β signal is intact,

the more sarcomatoid tumor is obtained through EMT. Among the previously described PDAC models, the tumors that had both *p16^{INK4a}* alleles inactivated demonstrated a higher frequency of sarcomatoid histology (Aguirre et al. 2003; Bardeesy et al. 2006), all of which seemed to have intact TGF- β signaling. The relation of *p16^{INK4a}* inactivation and EMT remains to be investigated. As described above, some areas of the *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{lox/lox}* tumor, however, showed E-cadherin mislocalization (Fig. 4), which might be associated with EMT. The *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{lox/lox}* PDAC cells have more E-cadherin dysfunction than the mPanIN cells, but might still retain more functional E-cadherin than other PDAC cells that showed a sarcomatoid pattern.

It has been reported that either the wild-type *p16^{INK4a}*, *Ink4a/Arf*, or *p53* allele was lost by LOH or inactivated by promoter methylation in the tumors of compound heterozygous genotype mice in the context of the *Pdx1-Cre;LSL-Kras^{G12D/+}* background (Bardeesy et al. 2006). Therefore, haploinsufficiency of TGF- β signal might be a unique mechanism in PDAC progression.

Different phenotypes of Tgfr2 knockout and Smad4 knockout in the context of active Kras expression

This study has demonstrated that blockade of TGF- β signaling might have significance in PDAC formation; however, mutation or deletion of the *Tgfr2* gene is found in <5% of human pancreatic cancer, among them especially in medullary carcinoma, a rare variant of pancreatic cancer (Goggins et al. 1998), although epigenetic silencing of *Tgfr2* may occur more frequently in human PDAC.

In contrast, the incidence of *Smad4* mutation or deletion is 55%. Therefore, one might suggest that the *Smad4* knockout (plus *Kras^{G12D}* expression) could provide a model more closely recapitulating human PDAC than that of the *Tgfr2* knockout plus *Kras^{G12D}* expression model (*Kras* + *Tgfr2*KO) presented here. Pancreas-specific *Smad4* knockout mice (*Pdx1-Cre;Smad4^{lox/lox}* and *Ptf1a^{cre/+};Smad4^{lox/lox}*) also showed normal pancreas development similar to the *Tgfr2* knockout (N. Bardeesy and R.A. DePinho, pers. comm.). In contrast, pancreas-specific *Kras^{G12D}* expression plus *Smad4* knockout (*Kras* + *Smad4*KO) mice (*Pdx1-Cre;LSL-Kras^{G12D/+};Smad4^{lox/lox}* and *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Smad4^{lox/lox}*) developed large pancreatic tumors by ~10 wk with 100% penetrance. However, the tumor phenotype of *Kras* + *Smad4*KO differed from the *Kras* + *Tgfr2*KO in that they were less aggressive. The *Kras* + *Smad4*KO mice developed intraductal papillary mucinous neoplasm (IPMN) that progressed to frank PDAC at low penetrance (N. Bardeesy and R.A. DePinho, pers. comm.); on the other hand, *Smad4* deficiency cooperated with *Kras^{G12D}* and *Ink4a/Arf* heterozygosity to promote rapid development of PDAC. The more aggressive character of the tumor in the *Kras* + *Tgfr2*KO compared with the *Kras* + *Smad4*KO (with intact *Ink4a/Arf*) might be explained by the idea that the knockout of

Tgfr2 abrogates all signaling downstream from the TGF- β receptors, having more impact than preventing only Smad4-dependent signal transduction. Since Smad4 is also a central signal mediator downstream from bone morphogenetic protein (BMP) and activin (Miyazono et al. 2000), one may suggest that blockade of BMP or activin signaling might be contributing to human PDAC progression. However, our study demonstrates that blockade of TGF- β signaling (with *Kras^{G12D}* expression) is sufficient to promote aggressive PDAC progression.

In conclusion, the *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{lox/lox}* mice present a promising PDAC model with a very close approximation, by several key criteria, to the severe aggressive form of the human disease. Further intensive investigation of this model will provide a better understanding of the lethal PDAC and assist in developing new therapies.

Materials and methods

Generating mouse lines

Tgfr2^{lox/lox} mice (C57BL/6) (Chytil et al. 2002) were mated with *Ptf1a^{cre/+}* mice (C57BL/6/DBA/2) (Kawaguchi et al. 2002) to generate *Ptf1a^{cre/+};Tgfr2^{lox/lox}* mice (C57BL/6/DBA/2). Then, the *Ptf1a^{cre/+}*, *Tgfr2^{lox/lox}*, and *LSL-Kras^{G12D/+}* mice (129/SvJae/C57BL/6) (Jackson et al. 2001) were interbred to obtain *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{lox/lox}*, *Ptf1a^{cre/+};LSL-Kras^{G12D/+};Tgfr2^{lox/lox}*, and littermate control mice on a mixed C57BL/6/DBA/2/129/SvJae background. Some mice were also bred with Rosa26 lacZ reporter mice (C57BL/6) (Soriano 1999) for the purpose of tracing Cre-recombinase expression driven by the *Ptf1a* promoter. All mice were housed in the Animal Care Facility at Vanderbilt University following the Association for the Assessment and Accreditation of Laboratory Animal Care guidelines.

Mouse genotyping and recombined allele detection

Genotyping of *Ptf1a^{cre}*, *LSL-Kras^{G12D}*, floxed *Tgfr2* alleles, and *LSL-Kras^{G12D}* and *Tgfr2* recombined allele detection were performed by using oligonucleotide primers as described previously (Jackson et al. 2001; Chytil et al. 2002; Kawaguchi et al. 2002; Hingorani et al. 2003; Cheng et al. 2005). Recombined alleles were detected by using genomic DNA extracted from paraffin-embedded pancreas and liver tissue.

Histopathology

Mouse tissue was harvested and processed as described before (Forrester et al. 2005). Immunohistochemistry for vimentin and smooth muscle actin was performed by the Vanderbilt Histology Core Facility. Other antibodies and procedures used are in the Supplemental Material.

Establishing primary pancreatic cell lines

Mouse pancreas cells were separated and cultured in Vitrogen/Fibronectin-coated dishes in the RPMI media supplemented with 20% fetal bovine serum and antibiotics to obtain pure pancreas epithelial cell populations (Aguirre et al. 2003; Forrester et al. 2005). After the cells reached pure population, all experiments were performed within eight passages, to avoid

possible gross genomic changes during long-term in vitro culture.

Molecular analysis of the primary pancreatic cell lines

RNA and protein of the primary mouse pancreatic cell lines were extracted for subsequent RT-PCR, sequencing, and Western blotting. Specific reagents and procedures are in the Supplemental Material.

Laser-capture microdissection

Epithelial tissue of primary pancreatic tumor, metastatic liver tumor, normal liver, and normal duodenum of the *Ptf1a^{cre/+}; LSL-Kras^{G12D/+}; Tgfbr2^{lox/+}* mice was microdissected by laser, and DNA was extracted as described before (Cheng et al. 2005). Subsequently, PCR was performed for detection of wild-type, floxed, and recombined alleles of *Tgfbr2*.

Other experimental procedures are described in the Supplemental Material.

Acknowledgments

We thank Phillippe Soriano for providing the ROSA26r mice, David A. Tuveson and Tyler Jacks for providing the *LSL-Kras^{G12D/+}* mice, and Nabeel Bardeesy and Ronald A. DePinho for useful technical information and helpful discussions. H.I. is supported by the Uehara Memorial Foundation. This work is supported by grants CA 085492 and CA 102162 to H.L.M. and the T.J. Martell foundation.

References

- Aguirre, A.J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D.A., Horner, J., Redston, M.S., and DePinho, R.A. 2003. Activated *Kras* and *Ink4a/Arf* deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. *Genes & Dev.* **17**: 3112–3126.
- Aikawa, T., Gunn, J., Spong, S.M., Klaus, S.J., and Korc, M. 2006. Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer. *Mol. Cancer Ther.* **5**: 1108–1116.
- Bardeesy, N., Aguirre, A.J., Chu, G.C., Cheng, K.H., Lopez, L.V., Hezel, A.F., Feng, B., Brennan, C., Weissleder, R., Mahmood, U., et al. 2006. Both p16(*Ink4a*) and the p19(*Arf*)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. *Proc. Natl. Acad. Sci.* **103**: 5947–5952.
- Bierie, B. and Moses, H.L. 2006. TGF- β and cancer. *Cytokine Growth Factor Rev.* **17**: 29–40.
- Bottinger, E.P., Jakubczak, J.L., Roberts, I.S., Mumy, M., Hemmati, P., Bagnall, K., Merlino, G., and Wakefield, L.M. 1997. Expression of a dominant-negative mutant TGF- β type II receptor in transgenic mice reveals essential roles for TGF- β in regulation of growth and differentiation in the exocrine pancreas. *EMBO J.* **16**: 2621–2633.
- Cheng, N., Bhowmick, N.A., Chytil, A., Gorska, A.E., Brown, K.A., Muraoka, R., Arteaga, C.L., Neilson, E.G., Hayward, S.W., and Moses, H.L. 2005. Loss of TGF- β type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF- α , MSP- and HGF-mediated signaling networks. *Oncogene* **24**: 5053–5068.
- Chytil, A., Magnuson, M.A., Wright, C.V., and Moses, H.L. 2002. Conditional inactivation of the TGF- β type II receptor using Cre:Lox. *Genesis* **32**: 73–75.
- Derynck, R., Akhurst, R.J., and Balmain, A. 2001. TGF- β signaling in tumor suppression and cancer progression. *Nat. Genet.* **29**: 117–129.
- Forrester, E., Chytil, A., Bierie, B., Aakre, M., Gorska, A.E., Sharif-Afshar, A.R., Muller, W.J., and Moses, H.L. 2005. Effect of conditional knockout of the type II TGF- β receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. *Cancer Res.* **65**: 2296–2302.
- Friess, H., Yamanaka, Y., Buchler, M., Ebert, M., Beger, H.G., Gold, L.I., and Korc, M. 1993. Enhanced expression of transforming growth factor β isoforms in pancreatic cancer correlates with decreased survival. *Gastroenterology* **105**: 1846–1856.
- Goggins, M., Shekher, M., Turnacioglu, K., Yeo, C.J., Hruban, R.H., and Kern, S.E. 1998. Genetic alterations of the transforming growth factor β receptor genes in pancreatic and biliary adenocarcinomas. *Cancer Res.* **58**: 5329–5332.
- Grotendorst, G.R. 1997. Connective tissue growth factor: A mediator of TGF- β action on fibroblasts. *Cytokine Growth Factor Rev.* **8**: 171–179.
- Hahn, S.A., Schutte, M., Hoque, A.T., Moskaluk, C.A., da Costa, L.T., Rozenblum, E., Weinstein, C.L., Fischer, A., Yeo, C.J., Hruban, R.H., et al. 1996. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. *Science* **271**: 350–353.
- Hezel, A.F., Kimmelman, A.C., Stanger, B.Z., Bardeesy, N., and Depinho, R.A. 2006. Genetics and biology of pancreatic ductal adenocarcinoma. *Genes & Dev.* **20**: 1218–1249.
- Hingorani, S.R., Petricoin, E.F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M.A., Ross, S., Conrads, T.P., Veenstra, T.D., Hitt, B.A., et al. 2003. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. *Cancer Cell* **4**: 437–450.
- Hingorani, S.R., Wang, L., Multani, A.S., Combs, C., Deramaudt, T.B., Hruban, R.H., Rustgi, A.K., Chang, S., and Tuveson, D.A. 2005. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. *Cancer Cell* **7**: 469–483.
- Hoshino, M., Nakamura, S., Mori, K., Kawauchi, T., Terao, M., Nishimura, Y.V., Fukuda, A., Fuse, T., Matsuo, N., Sone, M., et al. 2005. *Ptf1a*, a bHLH transcriptional gene, defines GABAergic neuronal fates in cerebellum. *Neuron* **47**: 201–213.
- Hruban, R.H., Adsay, N.V., Albores-Saavedra, J., Compton, C., Garrett, E.S., Goodman, S.N., Kern, S.E., Klimstra, D.S., Kloppel, G., Longnecker, D.S., et al. 2001. Pancreatic intraepithelial neoplasia: A new nomenclature and classification system for pancreatic duct lesions. *Am. J. Surg. Pathol.* **25**: 579–586.
- Hruban, R.H., Adsay, N.V., Albores-Saavedra, J., Anver, M.R., Biankin, A.V., Boivin, G.P., Furth, E.E., Furukawa, T., Klein, A., Klimstra, D.S., et al. 2006. Pathology of genetically engineered mouse models of pancreatic exocrine cancer: Consensus report and recommendations. *Cancer Res.* **66**: 95–106.
- Jackson, E.L., Willis, N., Mercer, K., Bronson, R.T., Crowley, D., Montoya, R., Jacks, T., and Tuveson, D.A. 2001. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. *Genes & Dev.* **15**: 3243–3248.
- Janda, E., Lehmann, K., Killisch, I., Jechlinger, M., Herzig, M., Downward, J., Beug, H., and Grunert, S. 2002. Ras and TGF β cooperatively regulate epithelial cell plasticity and metastasis: Dissection of Ras signaling pathways. *J. Cell Biol.* **156**: 299–313.
- Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Smigal, C., and

- Thun, M.J. 2006. Cancer statistics, 2006. *CA Cancer J. Clin.* **56**: 106–130.
- Kawaguchi, Y., Cooper, B., Gannon, M., Ray, M., MacDonald, R.J., and Wright, C.V. 2002. The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors. *Nat. Genet.* **32**: 128–134.
- Klimstra, D.S. and Longnecker, D.S. 1994. K-ras mutations in pancreatic ductal proliferative lesions. *Am. J. Pathol.* **145**: 1547–1550.
- Lu, S.L., Herrington, H., Reh, D., Weber, S., Bornstein, S., Wang, D., Li, A.G., Tang, C.F., Siddiqui, Y., Nord, J., et al. 2006. Loss of transforming growth factor- β type II receptor promotes metastatic head-and-neck squamous cell carcinoma. *Genes & Dev.* **20**: 1331–1342.
- Miyazono, K., ten Dijke, P., and Heldin, C.H. 2000. TGF- β signaling by Smad proteins. *Adv. Immunol.* **75**: 115–157.
- Offield, M.F., Jetton, T.L., Labosky, P.A., Ray, M., Stein, R.W., Magnuson, M.A., Hogan, B.L., and Wright, C.V. 1996. PDX-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum. *Development* **122**: 983–995.
- Oshima, M., Oshima, H., and Taketo, M.M. 1996. TGF- β receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. *Dev. Biol.* **179**: 297–302.
- Rozenblum, E., Schutte, M., Goggins, M., Hahn, S.A., Panzer, S., Zahurak, M., Goodman, S.N., Sohn, T.A., Hruban, R.H., Yeo, C.J., et al. 1997. Tumor-suppressive pathways in pancreatic carcinoma. *Cancer Res.* **57**: 1731–1734.
- Sanvito, F., Herrera, P.L., Huarte, J., Nichols, A., Montesano, R., Orci, L., and Vassalli, J.D. 1994. TGF- β 1 influences the relative development of the exocrine and endocrine pancreas in vitro. *Development* **120**: 3451–3462.
- Soriano, P. 1999. Generalized lacZ expression with the ROSA26 Cre reporter strain. *Nat. Genet.* **21**: 70–71.
- Venkatasubbarao, K., Ahmed, M.M., Mohiuddin, M., Swiderski, C., Lee, E., Gower Jr., W.R., Salhab, K.F., McGrath, P., Strodel, W., and Freeman, J.W. 2000. Differential expression of transforming growth factor- β receptors in human pancreatic adenocarcinoma. *Anticancer Res.* **20**: 43–51.
- Wagner, M., Kleeff, J., Friess, H., Buchler, M.W., and Korc, M. 1999. Enhanced expression of the type II transforming growth factor- β receptor is associated with decreased survival in human pancreatic cancer. *Pancreas* **19**: 370–376.
- Warshaw, A.L. and Fernandez-del Castillo, C. 1992. Pancreatic carcinoma. *N. Engl. J. Med.* **326**: 455–465.
- Werlin, S.L. 2004. Exocrine pancreas. In *Nelson textbook of pediatrics* (ed. R.E. Behrman), pp. 1298–1304. Saunders, St. Louis, MO.
- Zavadil, J. and Bottinger, E.P. 2005. TGF- β and epithelial-to-mesenchymal transitions. *Oncogene* **24**: 5764–5774.
- Zhang, H.T., Chen, X.F., Wang, M.H., Wang, J.C., Qi, Q.Y., Zhang, R.M., Xu, W.Q., Fei, Q.Y., Wang, F., Cheng, Q.Q., et al. 2004. Defective expression of transforming growth factor β receptor type II is associated with CpG methylated promoter in primary non-small cell lung cancer. *Clin. Cancer Res.* **10**: 2359–2367.
- Zhao, H., Shiina, H., Greene, K.L., Li, L.C., Tanaka, Y., Kishi, H., Igawa, M., Kane, C.J., Carroll, P., and Dahiya, R. 2005. CpG methylation at promoter site -140 inactivates TGF β 2 receptor gene in prostate cancer. *Cancer* **104**: 44–52.

Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor- β signaling in cooperation with active Kras expression

Hideaki Ijichi, Anna Chytil, Agnieszka E. Gorska, et al.

Genes Dev. 2006, **20**:

Access the most recent version at doi:[10.1101/gad.1475506](https://doi.org/10.1101/gad.1475506)

Supplemental Material

<http://genesdev.cshlp.org/content/suppl/2006/10/26/20.22.3147.DC1>

References

This article cites 37 articles, 16 of which can be accessed free at:
<http://genesdev.cshlp.org/content/20/22/3147.full.html#ref-list-1>

License

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).